



Jim Walls
T 203-393-1387
www.orthomedex.com
jim.walls@orthomedex.com

Industry:

- Pharma
- Biotech
- Medical Device
- Diagnostic
- Other Material

Management:

Executive Leadership

Jim Walls, Founder & CEO
Dave Sutton, VP Engineering
Hadassah Janumala PhD,
Dir. Life Science & Biomaterials

Board:

SECT Tech Group

Scientific Advisory Board:

Lakshmi Nair, PhD; UCHC
Kelly Kirker, PhD; MSU, CBE
Jesus Hernandez, BS, Hon. D
David Healy, MSc.

Number of Employees: 3

Finance

Auditor: DeFreitas & Minsky, LLP

Current Investors/Financing to

Date: Self Financed/ > \$100,000

Amount of Financing Sought:

\$1.43M to 'match' Medical
Valley/BMBF Internationalization
Research Collaboration Grant

Legal:

Corporate: E. Kipperman, JD;
Wiggin & Dana LLP

IP: Doug Denninger, Esq.

Executive Summary:

Company History:

OrthoMedex LLC was formed Nov. 2015 to commercialize orthopedic implants based on *bioactive glass* technology and IP developed by the company's Founder & CEO, Jim Walls.

Market Opportunity / Unmet Need:

Aseptic implant loosening and infection cause orthopedic implants to be 'revised' [removed & replaced]. This increases healthcare cost and leads to unnecessary patient morbidity & mortality. *Bioactive glass* technology has application within all orthopedic market segments. The Company's development efforts are focused on the \$6.6B WW [+6.4% YoY] trauma/fracture fixation and \$5B WW [+2.9% YoY] orthobiologic market segments.

Products/Services – Launched & Pipeline:

OrthoMedex LLC seeks to leverage the osteostimulative and antimicrobial attributes of *bioactive glass* to address the unmet implant fixation & infection control needs of the ortho. surgeon.

Commercial / Technical Milestones:

2017 Medical Valley EMN e.V. [Bavaria, Germany] endorsed OrthoMedex's *bioactive glass* technology with a 1.19MM € [\$1.43MM] Internationalization Collaboration Grant. Collaborators include: The Fraunhofer Institute, Translational Center of Regenerative Therapies; Friedrich-Alexander University, Institute of Biomaterials; & the University of Connecticut Health Center, Department of Orthopedic Surgery.

In Nov. 2017 OrthoMedex GmbH was formed, and in April 2018 a 14 member EU/Rizzoli Orthopedic Institute [Bologna Italy] consortium received EU Commission acceptance of a stage-1 [5.9MM€] Horizons 2020 grant proposal entitled: RESTORE, to develop personalized tissue-engineered meniscal implants. OrthoMedex will investigate enhanced bone/meniscal ligamentous attachment via *bioactive glass*.

Intellectual Property:

Seeding of *bioactive glass* particles within the interstices of 3D-printed/porous-coated orthopedic implants, and the trabecular structure of cancellous bone allografts, to stimulate osteoblast de novo bone matrix deposition and provide the implant with antimicrobial prophylaxis. 2 USPTO Patents Issued; 1 USPTO Patent Pending; 1 EPO Patent Pending

Competition: Emerging Competitors: 1) Woven Orthopedic Technologies, LLC; 2) Silver Bullet Technologies; 3) ECTB; 4) BonAlive Biomaterials. Major Ortho Cos: 1) Stryker; 2) Xtant Medical

Financial Projections (Unaudited):

Yr. 6 Revenue [3rd Yr. of Sales] = \$19.5MM; EBITDA = 19%

Please indicate primary purpose of Presentation:

* Investment